Toward a Further Elucidation: Role of Vertebral Artery Hypoplasia in Acute Ischemic Stroke.
 |
Related Articles |
Toward a Further Elucidation: Role of Vertebral Artery Hypoplasia in Acute Ischemic Stroke.
Eur Neurol. 2006 Jun 13;55(4):193-197
Authors: Chuang YM, Huang YC, Hu HH, Yang CY
Background and Purpose: Congenital vertebral artery (VA) hypoplasia is an uncommon embryonic variation of posterior circulation. The frequency of this congenital variation was reported to be 2-6% from autopsy and angiograms. The aim of our study was to elucidate the role of VA hypoplasia in acute ischemic stroke. Method: We examined 191 acute ischemic stroke patients (age 55.8 +/- 14.0 years). TOAST subtypes were determined. A cervical magnetic resonance angiogram was performed in every patient. A duplex study of bilateral VA with flow velocities and vessel diameter recording in the intertransverse (V2) segment was performed within 72 h after onset of ischemic stroke. The net VA flow volume was measured in each subject. Result: The overall incidence of a unilateral congenital hypoplastic VA was 11.51%, which was statistically higher especially in cases of brainstem/cerebellar infarction. Of these, subjects with VA hypoplasia had an etiological preponderance of the ‘large-artery atherosclerosis’ subtype and a topographic preponderance of ipsilateral posterior circulation infarction. Conclusions: Based on our results, VA hypoplasia seemed a contributing factor of acute ischemic stroke, especially in posterior circulation territories. Copyright (c) 2006 S. Karger AG, Basel.
PMID: 16772715 [PubMed - as supplied by publisher]
Related posts:
- Spinal cord and vertebral stroke: a paediatric case.
- Influence of gender on outcomes after intra-arterial thrombolysis for acute ischemic stroke.
- Wide-range C-reactive protein efficacy in acute ischemic stroke patients.
- Safety of Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke. Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Trial, Part I.
- Genetic Variants of Arachidonate 5-Lipoxygenase-Activating Protein, and Risk of Incident Myocardial Infarction and Ischemic Stroke. A Nested Case-Control Approach.